🇮🇳 India Stock Screener ← Switch market ⚡ HerAI

Senores Pharmaceuticals Limited SENORES NSEPHARMA

Healthcare · Drug Manufacturers - General · India
https://senorespharma.com
Company Profile ↓
₹1,224.10
+81.87% 1Y
Mkt Cap₹5,637.42 Cr
P/E43.30
P/B5.61
52W High₹1,550.90
52W Low₹673.05
Book Value₹235.10
EPS (TTM)₹28.27

Company Overview

Senores Pharmaceuticals Limited develops, manufactures, sells, and trades in pharmaceutical and allied products in India, the United States, the United Kingdom, Canada, and internationally. It offers pharmaceutical solutions, such as analgesic/antipyretic, anesthetics and allied products, antibacterial/antibiotic, antiviral, antifungal, antioxidants, antineoplastic, blood line, cardiovascular, neurology, antacid, and vitamin and mineral preparation solutions; and analgesic/anti-inflammatory/antipyretic, anti-diabetic, antimalarial, nutritional supplements, and urinary tract generics, as well as management and consultancy services. The company was incorporated in 2017 and is based in Ahmedabad, India.

Why Investors Should Care

Healthy Capital Returns

Return on capital employed stands at 15.6%.

Consistent Profit Growth

Net profit has compounded at 139.2% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 161.6% CAGR over the past five years.

Healthy Margins

Maintains a net profit margin of 18.7%.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.35.

Recent Developments

  • Mar 2026 Revenue of ₹632.63 Cr (+58.9% YoY); net profit ₹115.38 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +38.3%, earnings +43.5%.
  • 5-Year Trend Long-term compounding — revenue CAGR 161.6%, profit CAGR 139.2%.

Growth & Price Performance

Compounded Sales Growth

5 Years:161.63%
1 Year:38.30%

Compounded Profit Growth

5 Years:139.18%
1 Year:43.50%

Stock Price Performance

1 Year:+81.87%
6 Months:+37.36%
3 Months:-12.15%
1 Month:-12.73%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 63% of range
₹673.05 ₹1,550.90
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMAAbove
  • RSI (14)33.92 · Neutral
Price Performance
1M-12.73%
3M-12.15%
6M+37.36%
1Y+81.87%
Valuation vs Sector

P/E of 43.30 is above the sector median of 36.43 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 161.6% over 5 years.
  • Profit CAGR of 139.2% over 5 years.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
43.30
Industry PE
36.43
Forward P/E
24.68
PEG Ratio
-
Book Value
₹235.10
Price to Book
5.61
P/S
8.94
EV/EBITDA
32.96
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
161.63%
Profit 5Y
139.18%
Revenue (YoY)
38.30%
Earnings (YoY)
43.50%

Profitability & Returns

ROCE
15.61%
ROE
12.36%
ROA
7.19%
Profit Margin
18.72%
Op Margin
24.32%
Gross Margin
62.37%
EPS (Latest Qtr)
₹6.60
EPS (TTM)
₹28.27

Balance Sheet & Liquidity

Debt/Equity
0.35
Quick Ratio
1.71
Current Ratio
1.92
Debt
₹342.03 Cr
Total Assets
₹1,603.81 Cr
Current Assets
₹812.43 Cr
Working Capital
₹388.43 Cr

Ownership

Promoter Holding
54.93%
Chg in Prom Hold
0.42%
FII / Inst Holding
9.32%
Chg in FII Hold
-1.39%

Financial Snapshot

Enterprise Value
₹5,637.42 Cr
Total Revenue (TTM)
₹680.28 Cr
EBITDA
₹193.36 Cr
Free Cash Flow
₹-202.68 Cr
Operating Cash Flow
₹62.05 Cr
Shares Outstanding
₹4.61 Cr
Gross Margin
62.37%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 SENORES Senores Pharmaceuticals Limited NSEPHARMA 1,224.10 43.30 ₹5,637.42 Cr 0.00% 15.61% 12.36% 161.63% 139.18%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,745.10 34.62 ₹4.19 L Cr 0.91% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,190.00 83.58 ₹2.44 L Cr 0.32% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,553.80 72.74 ₹1.73 L Cr 0.81% 9.05% 25.79% 13.27% 20.22%
5 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,117.30 24.90 ₹1.11 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
6 LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA 631.35 164.41 ₹1.09 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 7,600.00 52.32 ₹1.09 L Cr 0.25% 19.20% 20.48% 14.85% 33.34%
8 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 2,012.50 99.48 ₹1.09 L Cr 0.12% 19.53% 16.77% 3.77% 4.00%
9 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,314.00 31.51 ₹1.06 L Cr 0.99% 14.86% 11.27% 7.23% 11.45%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue 79.00 Cr102.00 Cr80.00 Cr101.00 Cr--132.56 Cr153.36 Cr164.85 Cr175.19 Cr180.21 Cr
Cost of Revenue ------61.36 Cr57.08 Cr67.02 Cr66.22 Cr65.72 Cr
Gross Profit ------71.20 Cr96.28 Cr97.83 Cr108.97 Cr114.49 Cr
Operating Expenses 64.00 Cr80.00 Cr59.00 Cr77.00 Cr--48.45 Cr54.87 Cr51.70 Cr70.78 Cr70.67 Cr
Operating Income 12.00 Cr18.00 Cr17.00 Cr19.00 Cr--22.75 Cr41.41 Cr46.13 Cr38.19 Cr43.82 Cr
EBITDA 15.00 Cr22.00 Cr21.00 Cr23.00 Cr--37.52 Cr54.92 Cr57.79 Cr65.16 Cr56.57 Cr
Interest Expense 2.00 Cr3.00 Cr5.00 Cr5.00 Cr--5.04 Cr6.19 Cr5.33 Cr8.46 Cr7.17 Cr
Pretax Income 10.00 Cr18.00 Cr13.00 Cr16.00 Cr--26.49 Cr40.64 Cr44.60 Cr47.40 Cr39.46 Cr
Tax Provision 3.10 Cr3.42 Cr2.47 Cr2.88 Cr--5.31 Cr10.51 Cr11.02 Cr10.73 Cr9.01 Cr
Net Income 7.00 Cr14.00 Cr11.00 Cr13.00 Cr--19.73 Cr32.38 Cr31.66 Cr31.61 Cr30.72 Cr
Diluted EPS 2.375.233.233.86--4.606.547.297.966.60

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -35.33 Cr210.78 Cr398.25 Cr632.63 Cr
Cost of Revenue -12.77 Cr111.17 Cr180.70 Cr251.66 Cr
Gross Profit -22.56 Cr99.61 Cr217.55 Cr380.97 Cr
Operating Expenses -11.67 Cr67.87 Cr144.69 Cr243.90 Cr
Operating Income -10.89 Cr31.74 Cr72.86 Cr137.07 Cr
EBITDA -16.05 Cr43.46 Cr108.96 Cr215.38 Cr
Interest Expense -1.84 Cr8.50 Cr21.55 Cr25.03 Cr
Pretax Income -12.44 Cr24.94 Cr70.57 Cr159.10 Cr
Tax Provision -4.00 Cr-7.76 Cr12.23 Cr37.57 Cr
Net Income -8.43 Cr31.45 Cr58.57 Cr115.38 Cr
Diluted EPS -1.836.8316.1226.39

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -131.05 Cr621.88 Cr1,226.86 Cr1,603.81 Cr
Current Assets -51.34 Cr250.91 Cr722.43 Cr812.43 Cr
Cash & Equivalents -10.00 L7.65 Cr105.38 Cr45.55 Cr
Inventory -3.12 Cr37.37 Cr56.63 Cr89.29 Cr
Receivables -22.11 Cr112.01 Cr123.88 Cr324.82 Cr
Total Liabilities -85.55 Cr390.17 Cr414.61 Cr639.27 Cr
Current Liabilities -51.88 Cr247.50 Cr240.70 Cr424.00 Cr
Long Term Debt -29.73 Cr133.65 Cr162.46 Cr194.89 Cr
Total Debt -62.59 Cr257.64 Cr314.75 Cr342.03 Cr
Total Equity -45.50 Cr204.27 Cr786.19 Cr933.60 Cr
Shares Outstanding -4.61 Cr4.61 Cr4.61 Cr4.61 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow --1.08 Cr-25.70 Cr-45.92 Cr62.05 Cr
Investing Cash Flow --48.29 Cr-54.23 Cr-429.48 Cr-120.56 Cr
Financing Cash Flow -46.25 Cr86.98 Cr573.13 Cr-1.33 Cr
Capital Expenditure --47.28 Cr-51.83 Cr-157.52 Cr-264.73 Cr
Free Cash Flow --48.36 Cr-77.53 Cr-203.44 Cr-202.68 Cr
Net Change in Cash --3.12 Cr7.05 Cr97.73 Cr-59.84 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -63.9%47.3%54.6%60.2%
Operating Margin % -30.8%15.1%18.3%21.7%
Net Margin % -23.9%14.9%14.7%18.2%
ROE % -18.5%15.4%7.4%12.4%
ROCE % -13.8%8.5%7.4%11.6%

Shareholding Pattern

Insiders
54.93%
Institutions
9.32%
Public Float
20.68%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SENORES

Google News hu, 25 Jun 2026

SENORES Forecast — Price Target — Prediction for 2027 - TradingView

<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1xX1draGhsWXBOYjUzX190Rl95SkdEN3V0Ti05d2wyTTM5SDB2QXlyajk5Z0xVWndtckl0OU8xMlNVOEFjNEFmeEg2RHluS0h3Q2t6d3poV0V0cmNqLXd4UFg2dHdiT0N5LXllQlFpalRnNHhLWFNsWXN3?oc=5" target="_blank">SEN…

Google News ue, 28 Jul 2026

Senores Pharmaceuticals Ltd (NSE:SENORES) Q1 2027 Earnings Call Highlights: Robust Revenue ... - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPaEtrcGJYaWE0NmNNQ1NqSWQ3dmhfbXhLUXdvcFRIMWptSjJIWmVpbEU1TzR5T0NjRHJRaE42ejB3T1ZCQjFESmdjVWJWbHRtY0pXeGRZM1VFRmNJV3ROSXZNRzdRVW4wOWV3dVZtZFVPSGNiekRPV2dHZG9GNFE2YzlJSGtTdU5NWThqM3…

Google News Fri, 16 Oct 2026

Senores Pharmaceuticals seeks approval for MD and WTD re-appointments - scanx.trade

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxOTjRGVG0taE5pUXY0bGRHS0NRWGstZzhnSkVla2ZvNnFSSjJYUVpnSHNYY2ktMTNyMUpaV0RRczBvLUg2N1pHZlJLMzNTVTU1WlMyZGRtaTJ2aklmX2twUm5qZTFvMndOM0VLdW5raVVxSFl3bFpZbW1zS0hjZHFaNmpBbFBZbXJWX3Nsdm…

Google News Wed, 24 Jun 2026

Senores Pharmaceuticals - 5 stocks bought by FIIs, MFs and retail investors rally up to 60% in 6 months - The Economic Times

<a href="https://news.google.com/rss/articles/CBMigAJBVV95cUxOWGtvdmdXVzg5WEYwVUtqT3dKeFZ2T1cxMGlzMWlEM1dPdUM2akFIXzdCUlFfd1VieVZycTJpR05fLUpDY0Q0cXVvYVIxcFJTWkM0QjdnTmxON3VMcXB0VzlIbkhNNDdrUkxfdG9iZHg4cWtTaEdTcGtBVzNiY1M0ci1Fam8weEZyRnhqYW…

Google News Sat, 22 Aug 2026

Senores Pharma targets ₹3,000 crore revenue in 3-5 years, expands India and US capacity - CNBC TV18

<a href="https://news.google.com/rss/articles/CBMi_gFBVV95cUxOWEtFVjM2T0tKeUZjUkc5bTF0X1lVZWQ5SktQd2ZEV2RjZ2RfNWREM212WGlhQ2gzNmRqeS1GZUU4T2hhdmhwLWtXbVctc1hENVI0SkM5ZDE0ZzJtS3FobXNtUFBWVzNPamJMYjk2QUh3WTNqTDM1aUNEZURSVjIyb3FaV2t4am1RUld1Rm…

Google News ue, 28 Jul 2026

Buy Senores Pharma; target of Rs 1795: Choice Institutional Equities - Moneycontrol.com

<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxQWDVsNTBNWnFibEJ2a3VvVEJpNEduUjlfQUhHenhiYU4zMURFVkFvN0JOOXJzUFRJX04xaG1GYUV2X1VUX3A4WDl6aG96djRkeUFuaFlpME5zTTVndmlUb0RxUTZXYzdrak9ZTGJTN3ZVSDd0UVcyaVNKR0xPbktVSTJ5MmtSMTR4MGVPSX…

SENORES — Frequently Asked Questions

What is the current share price of Senores Pharmaceuticals Limited (SENORES)?

As of 2026-10-23 04:58 IST, Senores Pharmaceuticals Limited (SENORES) trades at ₹1,224.10 on NSE. Its 52-week range is ₹673.05 to ₹1,550.90.

What is the market capitalisation of SENORES?

Senores Pharmaceuticals Limited (SENORES) has a market capitalisation of ₹5,637.42 Cr on NSE.

What is the P/E ratio of SENORES?

SENORES trades at a trailing price-to-earnings (P/E) ratio of 43.30. The industry average P/E is 36.43. Its price-to-book (P/B) ratio is 5.61.

What is the return on equity (ROE) of SENORES?

SENORES has a return on equity (ROE) of 12.36%. Its return on capital employed (ROCE) is 15.61%.

Is SENORES a good stock to buy?

This page provides a data-driven analysis of Senores Pharmaceuticals Limited (SENORES), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space